Publications



2017

Hemmati P.G.; Vuong L.G.; Terwey T.H.; Jehn C.F.; Le Coutre P.; Penack O.; Na I.K.; Doerken B.; Arnold R.
Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation
European Journal of Haematology 98 (2): 160-168 (2017-02)



2016

Szyska M.; Na I.K.
Bone marrow GvHD after allogeneic hematopoietic stem cell transplantation
Frontiers in Immunology 7: 118 (2016-03-30)



2015

Hemmati P.G.; Terwey T.H.; Na I.K.; Jehn C.F.; le Coutre P.; Vuong L.G.; Doerken B.; Arnold R.
Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome
European Journal of Haematology 95 (6): 498-506 (2015-12)



Mensen A.; Krause T.; Hanitsch L.G.; Meisel C.; Kleint M.E.; Volk H.D.; Na I.K.; Scheibenbogen C.
Altered B-cell subsets and functional B-cell defects in selective IgM deficiency
Clinical Immunology 161 (2): 96-102 (2015-12)



Mensen A.; Oh Y.; Becker S.C.; Hemmati P.G.; Jehn C.; Westermann J.; Szyska M.; Goeldner H.; Doerken B.; Scheibenbogen C.; Arnold R.; Na I.K.
Apoptosis-susceptibility prolongs the lack of memory B cells in acute leukemic patients after allogeneic hematopoietic stem cell transplantation
Biology of Blood and Marrow Transplantation 21 (11): 1895–1906 (2015-11)



Zeiser R.; Burchert A.; Lengerke C.; Verbeek M.; Maas-Bauer K.; Metzelder S.K.; Spoerl S.; Ditschkowski M.; Ecsedi M.; Sockel K.; Ayuk F.; Ajib S.; de Fontbrune F.S.; Na I.K.; Penter L.; Holtick U.; Wolf D.; Schuler E.; Meyer E.; Apostolova P.; Bertz H.; Marks R.; Luebbert M.; Waesch R.; Scheid C.; Stoelzel F.; Ordemann R.; Bug G.; Kobbe G.; Negrin R.; Brune M.; Spyridonidis A.; Schmitt-Graeff A.; van der Velden W.; Huls G.; Mielke S.; Grigoleit G.U.; Kuball J.; Flynn R.; Ihorst G.; Du J.; Blazar B.R.; Arnold R.; Kroeger N.; Passweg J.; Halter J.; Socie G.; Beelen D.; Peschel C.; Neubauer A.; Finke J.; Duyster J.; von Bubnoff N.
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multi-center survey
Leukemia 29 (10): 2062–2068 (2015-10)



Na I.K.; Le Coutre P.
Emerging role of tyrosine kinases as drugable targets in cancer
Biomarker Insights 10 (S3): 29-31 (2015-09-10)



Hemmati P.G.; Terwey T.H.; Na I.K.; le Coutre P.; Jehn C.F.; Vuong L.G.; Doerken B.; Arnold R.
Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate risk karyotype in first complete remission
European Journal of Haematology 94 (5): 431-438 (2015-05)



2014

Mensen A.; Na I.K.; Haefer R.; Meerbach A.; Schlecht M.; Pietschmann M.L.; Gruhn B.
Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD
Journal of Cancer Research and Clinical Oncology 140 (11): 1971-1980 (2014-11)



Mensen A.; Joehrens K.; Anagnostopoulos I.; Demski S.; Oey M.; Stroux A.; Hemmati P.; Westermann J.; Blau O.; Wittenbecher F.; Movassaghi K.; Szyska M.; Thomas S.; Doerken B.; Scheibenbogen C.; Arnold R.; Na I.K.
Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT
Blood 124 (6): 963-972 (2014-08-07)



2013

Wittenbecher F.; Rieger K.; Dziubianau M.; Herholz A.; Mensen A.; Blau I.W.; Uharek L.; Doerken B.; Thiel A.; Na I.K.
Rabbit antithymocyte globulin induces rapid expansion of effector memory CD8 T cells without accelerating acute graft versus host disease
Leukemia Research Reports 2 (2): 82-85 (2013-09-27)



Mensen A.; Ochs C.; Stroux A.; Wittenbecher F.; Szyska M.; Imberti L.; Fillatreau S.; Uharek L.; Arnold R.; Doerken B.; Thiel A.; Scheibenbogen C.; Na I.K.
Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation
Journal of Translational Medicine 11 (1): 188 (2013-08-14)



Ghosh A.; Holland A.M.; Dogan Y.; Yim N.; Rao U.K.; Young L.F.; West M.L.; Singer N.V.; Lee H.; Na I.K.; Tsai J.J.; Jenq R.; Penack O.; Hanash A.M.; Lezcano C.; Murphy G.F.; Liu C.; Sadelain M.; Sauer M.G.; Sant'Angelo D.; van den Brink M.R.M.
PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating graft-versus-host-disease
Cancer Research 73 (15): 4687-4696 (2013-08-01)



Na I.K.; Wittenbecher F.; Dziubianau M.; Herholz A.; Mensen A.; Kunkel D.; Blau O.; Blau I.; Thiel E.; Uharek L.; Scheibenbogen C.; Rieger K.; Thiel A.
Rabbit antithymocyte globulin (Thymoglobulin(R)) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients
Haematologica 98 (1): 23-30 (2013-01)



2011

Hanash A.M.; Kappel L.W.; Yim N.L.; Nejat R.A.; Goldberg G.L.; Smith O.M.; Rao U.K.; Dykstra L.; Na I.K.; Holland A.M.; Dudakov J.A.; Liu C.; Murphy G.F.; Leonard W.J.; Heller G.; van den Brink M.R.M.
Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL
Blood 118 (2): 446-455 (2011-07-14)



Lu S.X.; Kappel L.W.; Charbonneau-Allard A.M.; Atallah R.; Holland A.M.; Turbide C.; Hubbard V.M.; Rotolo J.A.; Smith M.; Suh D.; King C.; Rao U.K.; Yim N.; Bautista J.L.; Jenq R.R.; Penack O.; Na I.K.; Liu C.; Murphy G.; Alpdogan O.; Blumberg R.S.; Macian F.; Holmes K.V.; Beauchemin N.; van den Brink M.R.M.
Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation
PLoS ONE 6 (7): e21611 (2011-07-06)



2010

Na I.K.; Markley J.C.; Tsai J.J.; Yim N.L.; Beattie B.J.; Klose A.D.; Holland A.M.; Ghosh A.; Rao U.K.; Stephan M.T.; Serganova I.; Santos E.B.; Brentjens R.J.; Blasberg R.G.; Sadelain M.; van den Brink M.R.M.
Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo
Blood 116 (11): e18-e25 (2010-09-16)



Lu S.X.; Holland A.M.; Na I.K.; Terwey T.H.; Alpdogan O.; Bautista J.L.; Smith O.M.; Suh D.; King C.; Kochman A.; Hubbard V.M.; Rao U.K.; Yim N.; Liu C.; Laga A.C.; Murphy G.; Jenq R.R.; Zakrzewski J.L.; Penack O.; Dykstra L.; Bampoe K.; Perez L.; Furie B.; Furie B.; van den Brink M.R.M.
Absence of P-selectin in recipients of allogeneic bone marrow transplantation ameliorates experimental graft-versus-host disease
Journal of Immunology 185 (3): 1912-1919 (2010-08-01)



Penack O.; Henke E.; Suh D.; King C.G.; Smith O.M.; Na I.K.; Holland A.M.; Ghosh A.; Lu S.X.; Jenq R.R.; Liu C.; Murphy G.F.; Lu T.T.; May C.; Scheinberg D.A.; Gao D.C.; Mittal V.; Heller G.; Benezra R.; van den Brink M.R.M.
Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth
Journal of the National Cancer Institute 102 (12): 894-908 (2010-06-16)



Guerreiro M.; Na I.K.; Letsch A.; Haase D.; Bauer S.; Meisel C.; Roemhild A.; Reinke P.; Volk H.D.; Scheibenbogen C.
Human peripheral blood and bone marrow Epstein-Barr virus-specific T-cell repertoire in latent infection reveals distinct memory T-cell subsets
European Journal of Immunology 40 (6): 1566-1576 (2010-06)



Na I.K.; Lu S.X.; Yim N.L.; Goldberg G.L.; Tsai J.; Rao U.; Smith O.M.; King C.G.; Suh D.; Hirschhorn-Cymerman D.; Palomba L.; Penack O.; Holland A.M.; Jenq R.R.; Ghosh A.; Tran H.; Merghoub T.; Liu C.; Sempowski G.D.; Ventevogel M.; Beauchemin N.; van den Brink M.R.M.
The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease
Journal of Clinical Investigation 120 (1): 343-356 (2010-01)



2009

Na I.K.; Letsch A.; Guerreiro M.; Bauer S.; Noack I.; Geginat J.; Reinke P.; Loesch M.; Kienapfel H.; Thiel E.; Volk H.D.; Scheibenbogen C.
Human bone marrow as a source to generate CMV-specific CD4+ T cells with multifunctional capacity
Journal of Immunotherapy 32 (9): 907-913 (2009-11)



Penack O.; Smith O.M.; Cunningham-Bussel A.; Liu X.; Rao U.; Yim N.; Na I.K.; Holland A.M.; Ghosh A.; Lu S.X.; Jenq R.R.; Liu C.; Murphy G.F.; Brandl K.; van den Brink M.R.M.
NOD2 regulates hematopoietic cell function during graft-versus-host disease
Journal of Experimental Medicine 206 (10): 2101-2110 (2009-09-28)



Jenq R.R.; King C.G.; Volk C.; Suh D.; Smith O.M.; Rao U.K.; Yim N.L.; Holland A.M.; Lu S.X.; Zakrzewski J.L.; Goldberg G.L.; Diab A.; Alpdogan O.; Penack O.; Na I.K.; Kappel L.W.; Wolchok J.D.; Houghton A.N.; Perales M.A.; van den Brink M.R.M.
Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation
Blood 113 (7): 1574-1580 (2009-02-12)



2008

Na I.K.; Scheibenbogen C.; Adam C.; Stroux A.; Ghadjar P.; Thiel E.; Keilholz U.; Coupland S.E.
Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis
Human Pathology 39 (12): 1751-1755 (2008-12)



Na I.K.; Busse A.; Scheibenbogen C.; Ghadjar P.; Coupland S.E.; Letsch A.; Loddenkemper C.; Stroux A.; Bauer S.; Thiel E.; Keilholz U.
Identification of truncated chemokine receptor 7 in human colorectal cancer unable to localize to the cell surface and unreactive to external ligands
International Journal of Cancer 123 (7): 1565-1572 (2008-10-01)



Busse A.; Kraus M.; Na I.K.; Rietz A.; Scheibenbogen C.; Driessen C.; Blau I.W.; Thiel E.; Keilholz U.
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits
Cancer 112 (3): 659-670 (2008-02-01)



2007

Letsch A.; Knoedler M.; Na I.K.; Kern F.; Asemissen A.M.; Keilholz U.; Loesch M.; Thiel E.; Volk H.D.; Scheibenbogen C.
CMV-specific central memory T cells reside in bone marrow
European Journal of Immunology 37 (11): 3063-3068 (2007-11)



Na I.K.; Keilholz U.; Letsch A.; Bauer S.; Asemissen A.M.; Nagorsen D.; Thiel E.; Scheibenbogen C.
Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells
Cancer Immunology Immunotherapy 56 (3): 391-396 (2007-03)



2006

Honczarenko M.; Glodek A.M.; Swierkowski M.; Na I.K.; Silberstein L.E.
Developmental stage-specific shift in responsiveness to chemokines during human B-cell development
Experimental Hematology 34 (8): 1093-1100 (2006-08)



Ghadjar P.; Coupland S.E.; Na I.K.; Noutsias M.; Letsch A.; Stroux A.; Bauer S.; Buhr H.J.; Thiel E.; Scheibenbogen C.; Keilholz U.
Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer
Journal of Clinical Oncology 24 (12): 1910-1916 (2006-04-20)



Godal R.; Keilholz U.; Uharek L.; Letsch A.; Asemissen A.M.; Busse A.; Na I.K.; Thiel E.; Scheibenbogen C.
Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2
Blood 107 (8): 3205-3211 (2006-04-15)



2005

Jahnke K.; Coupland S.E.; Na I.K.; Loddenkemper C.; Keilholz U.; Korfel A.; Stein H.; Thiel E.; Scheibenbogen C.
Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma
Blood 106 (1): 384-385 (2005-07-01)



Na I.K.; Kreuzer K.A.; Lupberger J.; Doerken B.; Coutre P.
Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML
Leukemia Research Reports 29 (3): 343-345 (2005-03-01)



Holdhoff M.; Kreuzer K.A.; Appelt C.; Scholz R.; Na I.K.; Hildebrandt B.; Riess H.; Jordan A.; Schmidt C.A.; Van Etten R.A.; Doerken B.; LeCoutre P.
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor
Blood Cells Molecules and Diseases 34 (2): 181-185 (2005-03-01)



2003

Le Coutre P.; Kreuzer K.A.; Na I.K.; Schwarz M.; Lupberger J.; Holdhoff M.; Baskaynak G.; Gschaidmeier H.; Platzbecker U.; Ehninger G.; Prejzner W.; Huhn D.; Schmidt C.A.
Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome
American Journal of Hematology 73 (4): 249-255 (2003-08)



Kreuzer K.A.; Le Coutre P.; Landt O.; Na I.K.; Schwarz M.; Schultheis K.; Hochhaus A.; Doerken B.
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique
Annals of Hematology 82 (5): 284-289 (2003-05)



2002

le Coutre P.; Kreuzer K.A.; Na I.K.; Lupberger J.; Holdhoff M.; Appelt C.; Schwarz M.; Mueller C.; Gambacorti-Passerini C.; Platzbecker U.; Bonnet R.; Ehninger G.; Schmidt C.A.
Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571
Blood Cells Molecules and Diseases 28 (1): 75-85 (2002-01)



2001

Kreuzer K.A.; Saborowski A.; Lupberger J.; Appelt C.; Na I.K.; le Coutre P.; Schmidt C.A.
Fluorescent 5'-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias
British Journal of Haematology 114 (2): 313-318 (2001-08)